Furthermore, EGFR inhibition by erlotinib, a small molecule inhibitor that binds to the intracellular tyrosine kinase domain, or treatment with oxaliplatin, a chemotherapy used to treat colorectal cancer, did not initiate increased secretion of EGF (Figure 3D). This evidence concerns the gene EGFR and colorectal cancer.